Romania
· Delayed Price · Currency is RON S.C. Ropharma Statistics
Total Valuation
S.C. Ropharma has a market cap or net worth of RON 92.03 million. The enterprise value is 240.41 million.
| Market Cap | 92.03M |
| Enterprise Value | 240.41M |
Important Dates
The last earnings date was Monday, September 9, 2024.
| Earnings Date | Sep 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
S.C. Ropharma has 511.27 million shares outstanding. The number of shares has increased by 0.90% in one year.
| Shares Outstanding | 511.27M |
| Shares Change (YoY) | +0.90% |
| Shares Change (QoQ) | +1.79% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.04% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.08 |
| PB Ratio | 0.39 |
| P/FCF Ratio | 3.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.64, with an EV/FCF ratio of 9.26.
| EV / Earnings | 6,853.16 |
| EV / Sales | 0.20 |
| EV / EBITDA | 5.64 |
| EV / EBIT | 11.40 |
| EV / FCF | 9.26 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.01 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 3.89 |
| Debt / FCF | 6.40 |
| Interest Coverage | 3.54 |
Financial Efficiency
Return on equity (ROE) is 2.00% and return on invested capital (ROIC) is 3.29%.
| Return on Equity (ROE) | 2.00% |
| Return on Assets (ROA) | 1.60% |
| Return on Capital (ROIC) | 3.29% |
| Revenue Per Employee | 986,598 |
| Profits Per Employee | 29 |
| Employee Count | 894 |
| Asset Turnover | 1.44 |
| Inventory Turnover | 5.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -3.24% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 54.01 |
| Average Volume (20 Days) | 49,101 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.C. Ropharma had revenue of RON 1.19 billion and earned 35,080 in profits. Earnings per share was 0.00.
| Revenue | 1.19B |
| Gross Profit | 270.69M |
| Operating Income | 21.09M |
| Pretax Income | 14.83M |
| Net Income | 35,080 |
| EBITDA | 31.70M |
| EBIT | 21.09M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 32.48 million in cash and 166.03 million in debt, giving a net cash position of -133.56 million or -0.26 per share.
| Cash & Cash Equivalents | 32.48M |
| Total Debt | 166.03M |
| Net Cash | -133.56M |
| Net Cash Per Share | -0.26 |
| Equity (Book Value) | 252.99M |
| Book Value Per Share | 0.47 |
| Working Capital | 6.37M |
Cash Flow
In the last 12 months, operating cash flow was 45.02 million and capital expenditures -19.07 million, giving a free cash flow of 25.96 million.
| Operating Cash Flow | 45.02M |
| Capital Expenditures | -19.07M |
| Free Cash Flow | 25.96M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 22.81%, with operating and profit margins of 1.78% and 0.00%.
| Gross Margin | 22.81% |
| Operating Margin | 1.78% |
| Pretax Margin | 1.25% |
| Profit Margin | 0.00% |
| EBITDA Margin | 2.67% |
| EBIT Margin | 1.78% |
| FCF Margin | 2.19% |
Dividends & Yields
S.C. Ropharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.90% |
| Shareholder Yield | -0.90% |
| Earnings Yield | 0.04% |
| FCF Yield | 28.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.C. Ropharma has an Altman Z-Score of 1.57. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.57 |
| Piotroski F-Score | n/a |